<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">
<meta name="generator" content="litedown 0.7">
<title></title>
<style type="text/css">
body {
  font-family: sans-serif;
  max-width: 800px;
  margin: auto;
  padding: 1em;
  line-height: 1.5;
  print-color-adjust: exact;
  -webkit-print-color-adjust: exact;
}
body, .abstract, code, .footnotes, footer, #refs, .caption { font-size: .9em; }
li li { font-size: .95em; }
ul:has(li > input[type="checkbox"]) { list-style: none; padding-left: 1em; }
*, :before, :after { box-sizing: border-box; }
a { color: steelblue; }
pre, img { max-width: 100%; }
pre { white-space: pre-wrap; word-break: break-word; }
pre code { display: block; padding: 1em; overflow-x: auto; }
code { font-family: 'DejaVu Sans Mono', 'Droid Sans Mono', 'Lucida Console', Consolas, Monaco, monospace; }
:not(pre, th) > code, code[class], div > .caption { background: #f8f8f8; }
pre > code:is(:not([class]), .language-plain, .language-none, .plain), .box, .figure, .table { background: inherit; border: 1px solid #eee; }
pre > code {
  &.message { border-color: #9eeaf9; }
  &.warning { background: #fff3cd; border-color: #fff3cd; }
  &.error { background: #f8d7da; border-color: #f8d7da; }
}
.fenced-chunk { border-left: 1px solid #666; }
.code-fence {
  opacity: .4;
  border: 1px dashed #666;
  border-left: 2px solid;
  &:hover { opacity: inherit; }
}
.box, .figure, .table, table { margin: 1em auto; }
div > .caption { padding: 1px 1em; }
.figure { p:has(img, svg), pre:has(svg) { text-align: center; } }
.flex-col { display: flex; justify-content: space-between; }
table {
  &:only-child:not(.table > *) { margin: auto; }
  th, td { padding: 5px; font-variant-numeric: tabular-nums; }
  thead, tfoot, tr:nth-child(even) { background: whitesmoke; }
  thead th { border-bottom: 1px solid #ddd; }
  &:not(.datatable-table) {
    border-top: 1px solid #666;
    border-bottom: 1px solid #666;
  }
}
blockquote {
  color: #666;
  margin: 0;
  padding: 1px 1em;
  border-left: .5em solid #eee;
}
hr, .footnotes::before { border: 1px dashed #ddd; }
.frontmatter { text-align: center; }
#TOC {
  a { text-decoration: none; }
  ul { list-style: none; padding-left: 1em; }
  & > ul { padding: 0; }
  ul ul { border-left: 1px solid lightsteelblue; }
}
.body h2 { border-bottom: 1px solid #666; }
.body .appendix, .appendix ~ h2 { border-bottom-style: dashed; }
.main-number::after { content: "."; }
span[class^="ref-number-"] { font-weight: bold; }
.ref-number-fig::after, .ref-number-tab::after { content: ":"; }
.cross-ref-chp::before { content: "Chapter "; }
.cross-ref-sec::before { content: "Section "; }
.cross-ref-fig::before, .ref-number-fig::before { content: "Figure "; }
.cross-ref-tab::before, .ref-number-tab::before { content: "Table "; }
.cross-ref-eqn::before, .MathJax_ref:has(mjx-mtext > mjx-c + mjx-c)::before { content: "Equation "; }
.abstract, #refs {
  &::before { display: block; margin: 1em auto; font-weight: bold; }
}
.abstract::before { content: "Abstract"; text-align: center; }
#refs::before { content: "Bibliography"; font-size: 1.5em; }
.ref-paren-open::before { content: "("; }
.ref-paren-close::after { content: ")"; }
.ref-semicolon::after { content: "; "; }
.ref-and::after { content: " and "; }
.ref-et-al::after { content: " et al."; font-style: italic; }
.footnote-ref a {
  &::before { content: "["; }
  &::after { content: "]"; }
}
section.footnotes {
  margin-top: 2em;
  &::before { content: ""; display: block; max-width: 20em; }
}
.fade {
  background: repeating-linear-gradient(135deg, white, white 30px, #ddd 32px, #ddd 32px);
  opacity: 0.6;
}

@media print {
  body { max-width: 100%; }
  tr, img { break-inside: avoid; }
}
@media only screen and (min-width: 992px) {
  body:not(.pagesjs) pre:has(.line-numbers):not(:hover) { white-space: pre; }
}
</style>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@xiee/utils@1.14.14/css/prism-xcode.min.css">
<script src="https://cdn.jsdelivr.net/npm/prismjs@1.29.0/components/prism-core.min.js" defer></script>
<script src="https://cdn.jsdelivr.net/npm/prismjs@1.29.0/plugins/autoloader/prism-autoloader.min.js" defer></script>
</head>
<body>
<div class="frontmatter">
</div>
<div class="body">
<h1 id="chp:epimap-myeloma-v2-0">EpiMAP Myeloma v2.0</h1>
<p><a href="https://www.gnu.org/licenses/gpl-3.0"><img src="https://img.shields.io/badge/License-GPLv3-blue.svg" alt="License: GPL v3" /></a>
<a href="https://www.stata.com/"><img src="https://img.shields.io/badge/Stata-15.0%2B-red.svg" alt="Stata" /></a>
<a href="https://doi.org/10.1371/journal.pone.0308812"><img src="https://img.shields.io/badge/DOI-10.1371%2Fjournal.pone.0308812-blue.svg" alt="DOI" /></a></p>
<p><strong>Epidemiological Modelling of Australian Patients with Myeloma</strong></p>
<p>A comprehensive discrete-event simulation model for multiple myeloma disease outcomes and treatment pathways, developed through collaboration between Monash University’s Centre for Health Economics and Transfusion Research Unit.</p>
<h2 id="sec:what-s-new-in-v2-0">What’s New in v2.0</h2>
<ul>
<li><strong>Reorganised Architecture</strong>: Clear version-specific folder structure (<code>v1.0/</code>, <code>v2.0/</code>)</li>
<li><strong>Extended Treatment Options</strong>: Additional pathways for later lines of therapy (LoT 3+)</li>
<li><strong>Robust Testing Framework</strong>: Complete model validation suite with benchmark results</li>
<li><strong>Comprehensive Documentation</strong>: Detailed user guides and technical specifications</li>
<li><strong>Improved Accuracy</strong>: Updated risk equations reflecting current clinical practice</li>
</ul>
<h2 id="sec:model-overview">Model Overview</h2>
<p>EpiMAP Myeloma simulates the complete treatment journey of multiple myeloma patients using <strong>30 evidence-based risk equations</strong> derived from the Australia and New Zealand Myeloma and Related Diseases Registry (MRDR).</p>
<h3 id="sec:key-features">Key Features</h3>
<ul>
<li><strong>Patient Characteristics</strong>: Age, sex, ECOG performance score, R-ISS staging</li>
<li><strong>Treatment Pathways</strong>: Comprehensive modelling of up to 9 lines of therapy</li>
<li><strong>Clinical Outcomes</strong>: Best Clinical Response (BCR) and Overall Survival (OS)</li>
<li><strong>ASCT Modelling</strong>: Separate pathways for transplant-eligible patients</li>
<li><strong>Maintenance Therapy</strong>: Post-induction treatment modelling</li>
<li><strong>Parametric Survival Models</strong>: Time-to-event analysis for all outcomes</li>
</ul>
<h2 id="sec:quick-start">Quick Start</h2>
<h3 id="sec:prerequisites">Prerequisites</h3>
<ul>
<li><strong>Stata 15.0 or higher</strong> (valid licence required)</li>
<li>Windows, macOS, or Linux operating system</li>
</ul>
<h3 id="sec:installation">Installation</h3>
<pre><code class="language-bash">git clone https://github.com/your-org/epimap-myeloma.git
cd epimap-myeloma/v2.0
</code></pre>
<h3 id="sec:basic-usage">Basic Usage</h3>
<pre><code class="language-stata">cd &quot;path/to/epimap-myeloma/v2.0&quot;
do &quot;EpiMAP_Myeloma_v2.0.do&quot; [Analysis] [Intervention] [Line] [Coefficients] [Data] [MinID] [MaxID] [Bootstrap] [MinBS] [MaxBS]
</code></pre>
<h4 id="sec:arguments-description">Arguments Description</h4>
<table>
<thead>
<tr>
<th align="center">Position</th>
<th align="left">Argument</th>
<th align="left">Description</th>
<th align="left">Example Values</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">1</td>
<td align="left"><strong>Analysis</strong></td>
<td align="left">Analysis identifier</td>
<td align="left"><code>vrdpost</code></td>
</tr>
<tr>
<td align="center">2</td>
<td align="left"><strong>Intervention</strong></td>
<td align="left">Treatment intervention</td>
<td align="left"><code>VRd</code>, <code>SoC</code></td>
</tr>
<tr>
<td align="center">3</td>
<td align="left"><strong>Line</strong></td>
<td align="left">Line of therapy (1-9)</td>
<td align="left"><code>1</code>, <code>2</code>, <code>3</code></td>
</tr>
<tr>
<td align="center">4</td>
<td align="left"><strong>Coefficients</strong></td>
<td align="left">Coefficient set to use</td>
<td align="left"><code>VRd</code>, <code>SoC</code></td>
</tr>
<tr>
<td align="center">5</td>
<td align="left"><strong>Data</strong></td>
<td align="left">Dataset type</td>
<td align="left"><code>Predicted</code>, <code>Population</code></td>
</tr>
<tr>
<td align="center">6</td>
<td align="left"><strong>MinID</strong></td>
<td align="left">Minimum patient ID</td>
<td align="left"><code>1</code></td>
</tr>
<tr>
<td align="center">7</td>
<td align="left"><strong>MaxID</strong></td>
<td align="left">Maximum patient ID</td>
<td align="left"><code>4884</code>, <code>1000</code></td>
</tr>
<tr>
<td align="center">8</td>
<td align="left"><strong>Bootstrap</strong></td>
<td align="left">Bootstrap flag (0/1)</td>
<td align="left"><code>0</code> (no), <code>1</code> (yes)</td>
</tr>
<tr>
<td align="center">9</td>
<td align="left"><strong>MinBS</strong></td>
<td align="left">Minimum bootstrap sample</td>
<td align="left"><code>1</code></td>
</tr>
<tr>
<td align="center">10</td>
<td align="left"><strong>MaxBS</strong></td>
<td align="left">Maximum bootstrap sample</td>
<td align="left"><code>5</code>, <code>100</code></td>
</tr>
</tbody>
</table>
<p>Example Commands</p>
<p>The simulation will generate <code>EpiMAP_Simulated_v2.dta</code> containing comprehensive patient outcomes.</p>
<h2 id="sec:repository-structure">Repository Structure</h2>
<ul>
<li><strong>v2.0/</strong>
<ul>
<li><code>EpiMAP_Myeloma_v2.0.do</code> - Main simulation script</li>
<li><strong>functions/</strong> - Core simulation functions
<ul>
<li><code>SIM_BCR_L*.do</code> - Best Clinical Response models</li>
<li><code>SIM_CR_L*.do</code> - Chemotherapy regimen selection</li>
<li><code>SIM_OS_*.do</code> - Overall survival models</li>
</ul>
</li>
<li><strong>data/</strong>
<ul>
<li><code>EpiMAP_Coefficients_v2.mmat</code> - Updated risk equation coefficients</li>
<li><code>EpiMAP_Patients_v2.dta</code> - Hypothetical patient dataset</li>
</ul>
</li>
<li><strong>analyses/</strong> - Specialised analysis scripts
<ul>
<li><strong>vrdpost/</strong> - VRd post-market analysis</li>
<li><strong>dvdpre/</strong> - DVd pre-market analysis</li>
</ul>
</li>
<li><strong>documentation/</strong> - Comprehensive user guides
<ul>
<li><code>User_Guide.md</code></li>
<li><code>Technical_Specifications.md</code></li>
<li><code>Parameter_Reference.md</code></li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="sec:clinical-applications">Clinical Applications</h2>
<h3 id="sec:treatment-regimens-modelled">Treatment Regimens Modelled</h3>
<p><strong>Line 1 (LoT 1)</strong></p>
<ul>
<li>VCd (Bortezomib, Cyclophosphamide, Dexamethasone): 58%</li>
<li>VRd (Bortezomib, Lenalidomide, Dexamethasone): 15%</li>
<li>Other regimens: 26%</li>
</ul>
<p><strong>Line 2 (LoT 2)</strong></p>
<ul>
<li>Rd (Lenalidomide, Dexamethasone): 16%</li>
<li>DVd (Daratumumab, Bortezomib, Dexamethasone): 11%</li>
<li>Other regimens: 73%</li>
</ul>
<p><strong>Lines 3-9 (LoT 3+)</strong></p>
<ul>
<li>Averaged survival benefit approach for emerging therapies</li>
</ul>
<h3 id="sec:risk-equations-30-total">Risk Equations (30 Total)</h3>
<table>
<thead>
<tr>
<th>Category</th>
<th>Equations</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Survival</strong></td>
<td>Overall Survival</td>
<td>Primary endpoint modelling</td>
</tr>
<tr>
<td><strong>Treatment Planning</strong></td>
<td>ASCT eligibility, regimen selection</td>
<td>Clinical decision support</td>
</tr>
<tr>
<td><strong>Response Prediction</strong></td>
<td>BCR for each LoT</td>
<td>Treatment effectiveness</td>
</tr>
<tr>
<td><strong>Time Intervals</strong></td>
<td>Chemotherapy duration, treatment-free periods</td>
<td>Disease progression modelling</td>
</tr>
</tbody>
</table>
<h2 id="sec:validation-and-performance">Validation and Performance</h2>
<ul>
<li><strong>Calibrated</strong> against MRDR registry data (2008-2023)</li>
<li><strong>Validated</strong> survival curves match observed patient outcomes</li>
<li><strong>Benchmarked</strong> treatment distributions reflect real-world practice</li>
<li><strong>Tested</strong> across diverse patient populations and scenarios</li>
</ul>
<h2 id="sec:advanced-usage">Advanced Usage</h2>
<h3 id="sec:custom-patient-populations">Custom Patient Populations</h3>
<p>Replace the hypothetical dataset with your institution’s data:</p>
<pre><code class="language-stata">// Edit line 24 in EpiMAP_Myeloma_v2.0.do
use &quot;your_patient_data.dta&quot;, clear
</code></pre>
<p><strong>Required variables</strong>: <code>age</code>, <code>male</code>, <code>ecog</code>, <code>iss</code></p>
<h3 id="sec:scenario-analyses">Scenario Analyses</h3>
<p>Run specific treatment comparisons:</p>
<pre><code class="language-stata">// VRd post-market analysis
do &quot;analyses/vrdpost/EpiMAP_Myeloma_Analysis_VRd-Post.do&quot;

// DVd pre-market analysis  
do &quot;analyses/dvdpre/EpiMAP_Myeloma_Analysis_DVd-Pre.do&quot;
</code></pre>
<h3 id="sec:bootstrap-validation">Bootstrap Validation</h3>
<p>Enable uncertainty quantification:</p>
<pre><code class="language-stata">global Bootstrap = 1
global BSMin = 1
global BSMax = 100
do &quot;EpiMAP_Myeloma_v2.0.do&quot;
</code></pre>
<h2 id="sec:output-variables">Output Variables</h2>
<p>The simulation generates comprehensive outcomes for each patient:</p>
<ul>
<li><strong>Survival</strong>: Overall survival time, mortality indicators</li>
<li><strong>Treatment</strong>: Regimen assignments, duration, response rates</li>
<li><strong>Progression</strong>: Treatment-free intervals, line progression</li>
<li><strong>Clinical</strong>: ASCT receipt, maintenance therapy, ECOG changes</li>
</ul>
<h2 id="sec:contributing">Contributing</h2>
<p>We welcome collaborative research! Please see our <a href="CONTRIBUTING.md">contribution guidelines</a> for:</p>
<ul>
<li>Bug reports and feature requests</li>
<li>Model validation with external datasets</li>
<li>Extension to new treatment regimens</li>
<li>Integration with health economic models</li>
</ul>
<h2 id="sec:documentation">Documentation</h2>
<ul>
<li><strong><a href="documentation/User_Guide.md">User Guide</a></strong>: Step-by-step instructions</li>
<li><strong><a href="documentation/Technical_Specifications.md">Technical Specifications</a></strong>: Detailed model description</li>
<li><strong><a href="documentation/Parameter_Reference.md">Parameter Reference</a></strong>: Complete coefficient listing</li>
<li><strong><a href="documentation/Migration_Guide.md">Migration Guide</a></strong>: Upgrading from v1.0</li>
</ul>
<h2 id="sec:citation">Citation</h2>
<h3 id="sec:primary-publication">Primary Publication</h3>
<blockquote>
<p>Irving A, Petrie D, Harris A, et al. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. <em>PLOS ONE</em>. 2024;19(8):e0308812. <a href="https://doi.org/10.1371/journal.pone.0308812">doi:10.1371/journal.pone.0308812</a></p>
</blockquote>
<h3 id="sec:software-citation">Software Citation</h3>
<pre><code class="language-bibtex">@software{epimap_myeloma_v2,
  title = {EpiMAP Myeloma: Epidemiological Modelling of Australian Patients with Myeloma},
  author = {Irving, Adam and Petrie, Dennis and Harris, Anthony and others},
  version = {2.0.0},
  year = {2025},
  url = {https://github.com/your-org/epimap-myeloma},
  institution = {Monash University}
}
</code></pre>
<h2 id="sec:research-team">Research Team</h2>
<p><strong>Health Economists</strong>: Adam Irving, Dennis Petrie, Anthony Harris, Laura Fanning</p>
<p><strong>Clinical Experts</strong>: Zoe K McQuilten, Erica M Wood, Bradley Augustson, Gordon Cook, Francesca Gay, Georgia McCaughan, Peter Mollee, Andrew Spencer</p>
<p><strong>Registry Team</strong>: Elizabeth Moore, Cameron Wellard, Neil Waters</p>
<p><strong>Consumer Representative</strong>: Andrew Marks</p>
<h2 id="sec:data-access">Data Access</h2>
<h3 id="sec:mrdr-patient-data">MRDR Patient Data</h3>
<p>For access to genuine patient data from the Australia and New Zealand Myeloma and Related Diseases Registry:</p>
<ul>
<li>Submit applications to the MRDR Steering Committee</li>
<li>Visit: <a href="https://www.mrdr.net.au/">mrdr.net.au</a></li>
</ul>
<h2 id="sec:licence">Licence</h2>
<p>This project is licensed under the GNU General Public License v3.0 - see the <a href="LICENSE">LICENSE</a> file for details.</p>
<h2 id="sec:support">Support</h2>
<ul>
<li><strong>Model Questions</strong>: <a href="mailto:adam.irving@monash.edu">adam.irving@monash.edu</a></li>
<li><strong>Technical Issues</strong>: <a href="https://github.com/your-org/epimap-myeloma/issues">Create an issue</a></li>
<li><strong>Collaboration Enquiries</strong>: Contact the research team</li>
</ul>
<h2 id="sec:related-resources">Related Resources</h2>
<ul>
<li><a href="https://www.mrdr.net.au/">Australia and New Zealand Myeloma and Related Diseases Registry</a></li>
<li><a href="https://www.monash.edu/business/che">Monash Centre for Health Economics</a></li>
<li><a href="https://www.monash.edu/medicine/sphpm/units/transfusion-research">Monash Transfusion Research Unit</a></li>
</ul>
<h2 id="sec:acknowledgements">Acknowledgements</h2>
<p>The EpiMAP Myeloma project was supported by grant 1200706 to Prof Zoe K McQuilten. We thank patients, clinicians, and research staff at participating centres for their invaluable contributions to the MRDR.</p>
<hr />
<p><strong>Important</strong>: This model is designed for research purposes. Clinical decisions should always involve qualified healthcare professionals and consider individual patient circumstances.</p>
</div>
</body>
</html>
